Novozymes, ThioLogics In Conjugation Platform Pact

Novozymes Biopharma has partnered with ThioLogics to offer serum-stable drug-albumin conjugation capabilities. The collaboration combines Novozymes’ modified recombinant human albumin (rAlbumin) Veltis technology, with ThioLogics’ site-specific maleimide conjugation platform, allowing Novozymes to offer serum stable albumin drug conjugates with enhanced pharmacokinetic and/or targeting capabilities. 
 
“Combining the benefits of Novozymes’ and ThioLogics’ technology platforms means that we can now work with more customers across a wider range of drug candidates,” said, Dermot Pearson, marketing director at Novozymes Biopharma. He continues, “Together we are creating new opportunities for customers by providing them with a single access point to link Novozymes’ Veltis albumins and ThioLogics’ conjugation platform, to improve their products.
  
“We are delighted to announce ThioLogics’ unique collaboration with Novozymes, which will expand the capabilities of our technology platform beyond antibody drug conjugates,” said Dr. Chris Williams, business development manager at ThioLogics.
 
Novozymes also recently partnered with Almac in the field of drug conjugation to support the use of the Veltis platform in peptide and protein fusion.